2019
Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non–Small Cell Lung Cancer
Uhlig J, Case MD, Blasberg JD, Boffa DJ, Chiang A, Gettinger SN, Kim HS. Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non–Small Cell Lung Cancer. JAMA Network Open 2019, 2: e199702. PMID: 31433481, PMCID: PMC6707019, DOI: 10.1001/jamanetworkopen.2019.9702.Peer-Reviewed Original ResearchMeSH KeywordsAblation TechniquesAdolescentAdultAgedAged, 80 and overAntineoplastic AgentsCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantComparative Effectiveness ResearchDatabases, FactualFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingPneumonectomyProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesSurvival RateTreatment OutcomeYoung AdultConceptsStage IV non-small cell lung cancerNon-small cell lung cancerPrimary tumor siteSuperior overall survivalSystemic therapySurgical resectionCell lung cancerExternal beam radiotherapyOverall survivalSurvival benefitLocal treatmentTumor siteTumor characteristicsLung cancerTreatment groupsMultivariable Cox proportional hazards regression modelsOligometastatic non-small cell lung cancerStage IV squamous cell carcinomaSurvival rateCox proportional hazards regression modelProportional hazards regression modelsComparative effectiveness research studyCancer-specific factorsNational Cancer DatabaseStage IV disease
2016
Lung Cancer in the Very Young: Treatment and Survival in the National Cancer Data Base
Arnold BN, Thomas DC, Rosen JE, Salazar MC, Blasberg JD, Boffa DJ, Detterbeck FC, Kim AW. Lung Cancer in the Very Young: Treatment and Survival in the National Cancer Data Base. Journal Of Thoracic Oncology 2016, 11: 1121-1131. PMID: 27103511, DOI: 10.1016/j.jtho.2016.03.023.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerNational Cancer Data BaseYounger patientsOlder patientsLung cancerRelative survivalStage IAdvanced stage non-small cell lung cancerCell lung cancerYears of ageAggressive therapyAggressive treatmentOverall survivalPatient demographicsPrimary outcomeTreatment patternsTumor characteristicsNSCLC casesPatientsStage IIIDetailed stagingSurvival informationOlder groupDistinct subsetsCancer
2010
Reduction of Elevated Plasma Osteopontin Levels With Resection of Non–Small-Cell Lung Cancer
Blasberg JD, Pass HI, Goparaju CM, Flores RM, Lee S, Donington JS. Reduction of Elevated Plasma Osteopontin Levels With Resection of Non–Small-Cell Lung Cancer. Journal Of Clinical Oncology 2010, 28: 936-941. PMID: 20085934, PMCID: PMC2834433, DOI: 10.1200/jco.2009.25.5711.Peer-Reviewed Original ResearchConceptsEarly-stage NSCLCPlasma osteopontin levelsPlasma OPN levelsOPN levelsEnzyme-linked immunosorbent assayPlasma OPNOsteopontin levelsWeeks postsurgeryElevated Plasma Osteopontin LevelsCell lung cancer correlatesUse of thoracotomyCell lung cancerLung cancer correlatesCancer-free smokersResectable NSCLCPerioperative eventsTumor characteristicsPresurgery levelsRecurrence rateValidation cohortLung cancerCancer correlatesTherapeutic responseNSCLCIndependent cohort